{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T16:24:33Z","timestamp":1778430273957,"version":"3.51.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s12185-024-03814-z","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T15:02:33Z","timestamp":1720105353000},"page":"297-304","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["High-dose cytarabine plus gemtuzumab ozogamicin as consolidation therapy in patients with favorable- or intermediate-risk acute myeloid leukemia"],"prefix":"10.1007","volume":"120","author":[{"given":"Shuki","family":"Oya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetoshi","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Morishige","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimi","family":"Maehiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Umeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Takaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshinobu","family":"Fukuyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maki","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutoshi","family":"Aoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiko","family":"Mouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4795-121X","authenticated-orcid":false,"given":"Koji","family":"Nagafuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,4]]},"reference":[{"issue":"11","key":"3814_CR1","doi-asserted-by":"publisher","first-page":"3678","DOI":"10.1182\/blood.V93.11.3678","volume":"93","author":"EL Sievers","year":"1999","unstructured":"Sievers EL, Appelbaum FR, Spielberger RT, Forman SJ, Flowers D, Smith FO, et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood. 1999;93(11):3678\u201384.","journal-title":"Blood"},{"issue":"13","key":"3814_CR2","doi-asserted-by":"publisher","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","volume":"19","author":"EL Sievers","year":"2001","unstructured":"Sievers EL, Larson RA, Stadtmauer EA, Estey E, L\u00f6wenberg B, Dombret H, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19(13):3244\u201354.","journal-title":"J Clin Oncol"},{"issue":"7","key":"3814_CR3","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1002\/cncr.21326","volume":"104","author":"RA Larson","year":"2005","unstructured":"Larson RA, Sievers EL, Stadtmauer EA, L\u00f6wenberg B, Estey EH, Dombret H, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005;104(7):1442\u201352.","journal-title":"Cancer"},{"issue":"24","key":"3814_CR4","doi-asserted-by":"publisher","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","volume":"121","author":"SH Petersdorf","year":"2013","unstructured":"Petersdorf SH, Kopecky KJ, Slovak M, Willman C, Nevill T, Brandwein J, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121(24):4854\u201360. https:\/\/doi.org\/10.1182\/blood-2013-01-466706.","journal-title":"Blood"},{"issue":"9825","key":"3814_CR5","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/s0140-6736(12)60485-1","volume":"379","author":"S Castaigne","year":"2012","unstructured":"Castaigne S, Pautas C, Terre C, Raffoux E, Bordessoule D, Bastie JN, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet (London, England). 2012;379(9825):1508\u201316. https:\/\/doi.org\/10.1016\/s0140-6736(12)60485-1.","journal-title":"Lancet (London, England)"},{"issue":"9","key":"3814_CR6","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/s1470-2045(14)70281-5","volume":"15","author":"RK Hills","year":"2014","unstructured":"Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;15(9):986\u201396. https:\/\/doi.org\/10.1016\/s1470-2045(14)70281-5.","journal-title":"Lancet Oncol"},{"issue":"7","key":"3814_CR7","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1111\/j.1349-7006.2011.01957.x","volume":"102","author":"N Usui","year":"2011","unstructured":"Usui N, Takeshita A, Nakaseko C, Dobashi N, Fujita H, Kiyoi H, et al. Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia (AML): Japan Adult Leukemia Study Group (JALSG)-AML206 study. Cancer Sci. 2011;102(7):1358\u201365. https:\/\/doi.org\/10.1111\/j.1349-7006.2011.01957.x.","journal-title":"Cancer Sci"},{"issue":"4","key":"3814_CR8","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424\u201347.","journal-title":"Blood"},{"issue":"1","key":"3814_CR9","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3343\/alm.2013.33.1.60","volume":"33","author":"Y Jeon","year":"2013","unstructured":"Jeon Y, Seo SW, Park S, Park S, Kim SY, Ra EK, et al. Identification of two novel NPM1 mutations in patients with acute myeloid leukemia. Ann Lab Med. 2013;33(1):60\u20134.","journal-title":"Ann Lab Med"},{"issue":"3","key":"3814_CR10","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48(3):452\u20138. https:\/\/doi.org\/10.1038\/bmt.2012.244.","journal-title":"Bone Marrow Transplant"},{"issue":"21","key":"3814_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1182\/blood.V118.21.79.79","volume":"118","author":"J Delaunay","year":"2011","unstructured":"Delaunay J, Recher C, Pigneux A, Witz F, Vey N, Blanchet O, et al. Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation. Results of the GOELAMS AML 2006 IR study. Blood. 2011;118(21):79.","journal-title":"Blood."},{"issue":"9825","key":"3814_CR12","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/s0140-6736(12)60485-1","volume":"379","author":"S Castaigne","year":"2012","unstructured":"Castaigne S, Pautas C, Terr\u00e9 C, Raffoux E, Bordessoule D, Bastie JN, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet (London, England). 2012;379(9825):1508\u201316. https:\/\/doi.org\/10.1016\/s0140-6736(12)60485-1.","journal-title":"Lancet (London, England)"},{"issue":"23","key":"3814_CR13","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1182\/blood.V126.23.320.320","volume":"126","author":"K Naeem","year":"2015","unstructured":"Naeem K, Hills RK, Virgo P, Couzens S, Clark N, Gilkes A, et al. Significance of blast CD33 expression for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukemia: results from the UK NCRI AML16\/17 trials. Blood. 2015;126(23):320.","journal-title":"Blood"},{"issue":"8","key":"3814_CR14","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1182\/blood.2019003471","volume":"135","author":"E Fournier","year":"2020","unstructured":"Fournier E, Duployez N, Ducourneau B, Raffoux E, Turlure P, Caillot D, et al. Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia. Blood. 2020;135(8):542\u20136. https:\/\/doi.org\/10.1182\/blood.2019003471.","journal-title":"Blood"},{"issue":"6","key":"3814_CR15","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1200\/jco.19.01406","volume":"38","author":"RF Schlenk","year":"2020","unstructured":"Schlenk RF, Paschka P, Krzykalla J, Weber D, Kapp-Schwoerer S, Gaidzik VI, et al. Gemtuzumab ozogamicin in NPM1-mutated acute myeloid leukemia: early results from the prospective randomized AMLSG 09\u201309 phase III study. J Clin Oncol. 2020;38(6):623\u201332. https:\/\/doi.org\/10.1200\/jco.19.01406.","journal-title":"J Clin Oncol"},{"issue":"7","key":"3814_CR16","doi-asserted-by":"publisher","first-page":"e495","DOI":"10.1016\/s2352-3026(23)00089-3","volume":"10","author":"H D\u00f6hner","year":"2023","unstructured":"D\u00f6hner H, Weber D, Krzykalla J, Fiedler W, K\u00fchn MWM, Schroeder T, et al. Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09\u201309): a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2023;10(7):e495\u2013509. https:\/\/doi.org\/10.1016\/s2352-3026(23)00089-3.","journal-title":"Lancet Haematol"},{"issue":"10","key":"3814_CR17","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.3324\/haematol.2011.043786","volume":"96","author":"MS De Propris","year":"2011","unstructured":"De Propris MS, Raponi S, Diverio D, Milani ML, Meloni G, Falini B, et al. High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation. Haematologica. 2011;96(10):1548.","journal-title":"Haematologica."},{"issue":"2","key":"3814_CR18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3324\/haematol.2010.034447","volume":"97","author":"P Hirsch","year":"2012","unstructured":"Hirsch P, Tang R, Marzac C, Perrot JY, Fava F, Bernard C, et al. Prognostic impact of high ABC transporter activity in 111 adult acute myeloid leukemia patients with normal cytogenetics when compared to FLT3, NPM1 CEBPA and BAALC. Haematologica. 2012;97(2):241\u20135. https:\/\/doi.org\/10.3324\/haematol.2010.034447.","journal-title":"Haematologica"},{"issue":"6","key":"3814_CR19","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1182\/bloodadvances.2019001335","volume":"4","author":"G Juliusson","year":"2020","unstructured":"Juliusson G, J\u00e4dersten M, Deneberg S, Lehmann S, M\u00f6llg\u00e5rd L, Wennstr\u00f6m L, et al. The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting. Blood Adv. 2020;4(6):1094\u2013101. https:\/\/doi.org\/10.1182\/bloodadvances.2019001335.","journal-title":"Blood Adv"},{"issue":"15","key":"3814_CR20","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1182\/blood.2022016293","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Roboz GJ, Montesinos P, Thol FR, Ravandi F, et al. Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine. Blood. 2022;140(15):1674\u201385. https:\/\/doi.org\/10.1182\/blood.2022016293.","journal-title":"Blood"},{"issue":"1","key":"3814_CR21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s12185-023-03567-1","volume":"118","author":"N Miyashita","year":"2023","unstructured":"Miyashita N, Onozawa M, Yoshida S, Kimura H, Takahashi S, Yokoyama S, et al. Prognostic impact of FLT3-ITD, NPM1 mutation and CEBPA bZIP domain mutation in cytogenetically normal acute myeloid leukemia: a Hokkaido Leukemia Net study. Int J Hematol. 2023;118(1):36\u201346. https:\/\/doi.org\/10.1007\/s12185-023-03567-1.","journal-title":"Int J Hematol"},{"issue":"7","key":"3814_CR22","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1200\/JCO.2015.62.6846","volume":"34","author":"JA Pollard","year":"2016","unstructured":"Pollard JA, Loken M, Gerbing RB, Raimondi SC, Hirsch BA, Aplenc R, et al. CD33 expression and its association with gemtuzumab ozogamicin response: results from the randomized phase III Children\u2019s Oncology Group Trial AAML0531. J Clin Oncol. 2016;34(7):747.","journal-title":"J Clin Oncol"},{"issue":"4","key":"3814_CR23","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1182\/blood-2017-08-802157","volume":"131","author":"RE Gale","year":"2018","unstructured":"Gale RE, Popa T, Wright M, Khan N, Freeman SD, Burnett AK, et al. No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC\/NCRI trials. Blood. 2018;131(4):468\u201371.","journal-title":"Blood"},{"issue":"1","key":"3814_CR24","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1073\/pnas.1517951112","volume":"113","author":"F Schwarz","year":"2016","unstructured":"Schwarz F, Springer SA, Altheide TK, Varki NM, Gagneux P, Varki A. Human-specific derived alleles of CD33 and other genes protect against postreproductive cognitive decline. Proc Natl Acad Sci. 2016;113(1):74\u20139.","journal-title":"Proc Natl Acad Sci"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03814-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-024-03814-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03814-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T11:30:48Z","timestamp":1724931048000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-024-03814-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,4]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["3814"],"URL":"https:\/\/doi.org\/10.1007\/s12185-024-03814-z","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,4]]},"assertion":[{"value":"4 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}